ReviewBioengineering (Basel, Switzerland)2025
Advances and Applications of Organ-on-a-Chip and Tissue-on-a-Chip Technology.
Review in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multi-step femtosecond laser-fabricated membranes for regulated migration of biomolecules and cells.bioRxiv : the preprint server for biology · 2026Article
- Crosstalk between innate immune signaling pathways and integrated TLR, NLRP3 inflammasome, cGAS-STING, and NF-κB networks in sepsis.Frontiers in cell and developmental biology · 2026Review
- Significance of innate immune surveillance in emphysematous pancreatitis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organ-on-a-chip (OoC) or tissue-on-a-chip (ToC) technologies represent a significant advancement in enabling modeling of human organ and tissue physiology for medical study, although further development is required for these technologies to reach widespread adoption. OoC/ToC are three-dimensional (3D) microfluidic platforms that overcome limitations of traditional two-dimensional (2D) cell culture or animal models, providing an alternative environment for disease study, drug interactions, and tissue regeneration. The design of these systems is complex, requiring advanced fabrication techniques and careful selection of biomaterials with consideration of material toxicity, optical clarity, stability, and flexibility. A key innovation in this field is the multi-organ-on-a-chip (MOC) technology, which links multiple organ systems on a single platform. This enables the study of systemic diseases and the complex communication between organs, which is not possible with single-organ models. Furthermore, OoC/ToC technology holds immense potential for personalized medicine. By using patient-specific cells, these devices can create disease models that reflect an individual's unique genetic and phenotypic variations, paving the way for tailored therapeutic interventions. The integration of real-time sensors within these devices also facilitates high-throughput screening and accelerates drug discovery. While the development and optimization of these systems is still in its early stages, OoC/ToC technologies have already demonstrated promise in a number of translational research applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.